5 Best Gene Therapy Stocks to Buy in 2026

4. 4D Molecular Therapeutics Inc (NASDAQ:FDMT)

Stock Upside Potential: 195.62%

Number of Hedge Fund Holders: 36

4D Molecular Therapeutics Inc (NASDAQ:FDMT) is one of the best gene therapy stocks to buy in 2026. The stock has gained nearly 30% year-to-date and surged more than 190% over the past year. Looking ahead, analysts expect FDMT stock to almost triple in the next 12 months as the company continues to advance its clinical programs.

On May 7, 4D Molecular Therapeutics reported its Q1 2026 results and issued operational updates. On the financial side, the company said that it expects to have enough cash to fund its operations at least into the second half of 2028. It closed Q1 with $458 million in cash, cash equivalents, and marketable securities. The company also expects to receive some payments under its arrangement with Otsuka.

Regarding its clinical programs, 4D Molecular Therapeutics said it completed enrollment in the 4FRONT-1 Phase 3 trial of 4D-150 ahead of schedule. It said this demonstrates strong investigator and patient enthusiasm for the study. It expects topline data from this study in the first half of 2027. The company expects to complete enrollment in the 4FRONT-2 Phase 3 trial of 4D-150 in the back half of 2026 and expects topline data readout in the second half of 2027.

4D Molecular is developing 4D-150 as a therapy for blinding retinal vascular diseases. The lead indication is wet age-related macular degeneration, which is the subject of the 4FRONT Phase 3 studies. Another indication is diabetic macular edema. 4D Molecular is also advancing programs for geographic atrophy and cystic fibrosis therapies.

California-based 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is a biotech company focused on genetic medicines. The company is developing advanced gene therapies that target rare and common diseases in areas like ophthalmology and pulmonology.

1281292 - 11759070 - 1